Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
13.19
Price to sales ratio
1.79

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2474
PCRX
Pacira BioSciences, Inc. - Common Stock
25.20 USD-1.33%-3.00%+9.33%+15.44%991.57 M USD
2485
BIOA
BioAge Labs, Inc. - Common Stock
22.79 USD+4.59%-6.90%+24.60%+199.87%1.01 B USD
2611
ESPR
Esperion Therapeutics, Inc. - Common Stock
3.18 USD0.00%+0.63%+0.63%+169.49%818.63 M USD
2631
EVO
Evotec SE - American Depositary Shares each representing 1/2 of
2.14 USD-11.93%-24.91%-24.11%-49.88%760.89 M USD

Frequently asked questions about Amphastar Pharmaceuticals, Inc. - Common Stock

What is the Amphastar Pharmaceuticals, Inc. - Common Stock stock price today?

The current price of Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH) is 18.62. Over the past 24 hours, the stock has changed by -3.47%. Follow the AMPH chart for real-time price dynamics.

What is the stock ticker of Amphastar Pharmaceuticals, Inc. - Common Stock?

Amphastar Pharmaceuticals, Inc. - Common Stock trades under the ticker AMPH. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Amphastar Pharmaceuticals, Inc. - Common Stock stock going up?

AMPH has changed by -7.32% over the last week, -7.41% over the last month, and -23.63% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Amphastar Pharmaceuticals, Inc. - Common Stock net income for the last quarter?

Amphastar Pharmaceuticals, Inc. - Common Stock reported net income of 6.42 M for the last quarter. The previous quarter showed 24.43 M, which means net income changed by -73.72%.

How many employees does Amphastar Pharmaceuticals, Inc. - Common Stock have?

As of the latest available data, Amphastar Pharmaceuticals, Inc. - Common Stock has 1 976 employees. Workforce size can provide additional context about the company's scale and operations.

What is Amphastar Pharmaceuticals, Inc. - Common Stock EBITDA?

Amphastar Pharmaceuticals, Inc. - Common Stock EBITDA is 28.77 M, and its EBITDA margin is 16.81%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Amphastar Pharmaceuticals, Inc. - Common Stock stock?

You can buy Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Amphastar Pharmaceuticals, Inc. - Common Stock stock?

Investing in Amphastar Pharmaceuticals, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the AMPH chart and related analysis on metatrader.com as part of your research.

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.

News